About Us /
Doug Treco, Ph.D., Co-Founder, President and CEO
Doug has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc),a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. Previously, he was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School. He has authored numerous peer-reviewed publications and holds over 35 U.S. and European patents in the areas of protein production, gene mapping, and gene therapy. Doug is also an Entrepreneur-in-Residence with Morgenthaler Ventures. Doug received his Ph.D. in biochemistry and molecular biology from SUNY at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.
Pamela Esposito, Ph.D., Chief Business Officer
Pamela joins Ra as CBO with broad experience in building innovative drug discovery companies in oncology and creating high value alliances within the industry. Most recently, Pamela was at Angiochem Inc, a peptide- conjugate platform company where she lead strategic planning and all aspects of corporate development. In this role, she was instrumental in putting in place several important collaborations for the company. Prior to Angiochem, Pamela was vice president of business development at Biovex, a clinical stage oncology company focused on melanoma. In 2011, she was responsible for driving the successful acquisition of Biovex by Amgen. Before joining Biovex, she led business development and commercialization at Vion Pharmaceuticals and has been one of the first employees at a number of successful early stage companies, including Galenea and Bioduro (sold to PPD in 2009). Pamela received a B.A. from Dartmouth College and a Ph.D. in Pharmacology and Experimental Therapeutics from Tufts University School of Medicine where her research focused on the physiologic regulation of the blood-brain-barrier and the implications on drug distribution.
Kerry Black, M.S., M.B.A., Executive Director, Operations
Kerry joined Ra Pharma™ in March of 2010 as the Senior Director of Operations. She has over 20 years experience in the biotechnology industry working both as a Research Scientist and Operations Director. She has spent the last 10 years specializing in early stage companies, building business and operational infrastructure, including as an early employee at Critical Therapeutics, TetraPhase Pharmaceuticals and SetPoint Medical Corporation. Kerry received dual Bachelor of Science Degrees in molecular and cellular biology and biochemistry from the University of Maine. She received a Master of Chemistry Degree from the University of Massachusetts at Lowell and an MBA from the F.W. Olin School of Management at Babson College.
Kristopher Josephson, Ph.D., Director, Molecular Biology
Kris joined Ra Pharma™ as the Director of Molecular Biology in March of 2010. Previously he was a Senior Principal Investigator at EMD-Serono where he used fragment-based screening and structure-based drug design to discover and optimize kinase inhibitors. Kris was a postdoctoral fellow with Professor Jack W. Szostak at Massachusetts General Hospital and the Howard Hughes Medical Institute. There, he developed a system for the ribosomal synthesis of peptide libraries assembled from drug-like amino acids, which forms the basis for Ra Pharma™’s peptide discovery platform. Kris received his Ph.D. in microbiology from the University of Alabama at Birmingham. For his thesis project with Professor Mark R. Walter, Kris utilized X-ray crystallography and protein engineering to study the signaling mechanisms of cytokines.